Nelson's syndrome management: current knowledge;Prise en charge du syndrome de Nelson : données actuelles

Revue de Medecine Interne

Volumn 28, Issue 11, 2007, Pages 766-769

  Garcia, C ^a   Bordier, L ^a   Garcia Hejl, C ^a   Ceppa, F ^a   Mayaudon, H ^a   Dupuy, O ^a   Bauduceau, B ^a  

^a SERVICE D ENDOCRINOLOGIE   (France)

Author keywords

Cabergoline; Nelson's syndrome; Pituitary adenoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CYPROHEPTADINE; SOMATOSTATIN; VALPROIC ACID; CORTICOTROPIN; HISTAMINE H1 RECEPTOR ANTAGONIST;

DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; NELSON SYNDROME; SHORT SURVEY; TREATMENT OUTCOME; ADOLESCENT; ADRENALECTOMY; ARTICLE; BIOSYNTHESIS; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; FEMALE;

ADOLESCENT; ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; CUSHING SYNDROME; CYPROHEPTADINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; NELSON SYNDROME;

EID: 35349003519     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2007.05.018     Document Type: Short Survey

References (20)

1. Nelson D.H., Meakin J.W., Dealy J.B., Matson D.D., Emerson K., and Thorn G.W. ACTH producing tumor of the pituitary gland. N. Engl. J. Med. 259 (1958) 161-164
2. Assie G., Bahurel H., Bertherat J., Kujas M., Legmann P., and Bertagna X. The Nelson's syndrome revisited. Pituitary 7 (2004) 209-215
3. Jenkins P.J., Trainer P.J., Plowman P.N., Shand W.S., Grossman A.B., Wass J.A., et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J. Clin. Endocrinol. Metab. 80 (1995) 165-171
4. Pollock B.E., and Young Jr. W.F. Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 639-641
5. Assie G., Bahurel H., Coste J., Silvera S., Kujas M., Dugue M.A., et al. Corticotroph tumor progession after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J. Clin. Endocrinol. Metab. 92 (2007) 172-179
6. Kelly P.A., Samandouras G., Grossman A.B., Afshar F., Besser M., and Jenkins P.J. Neurosurgical treatment of Nelson's Syndrome. J. Clin. Endocrinol. Metab. 87 (2002) 5465-5469
7. Jane Jr. J.A., Vance M.L., Woodburn C.J., and Laws Jr. E.R. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg. Focus 14 (2003) e12
8. Kelly W., Adams J.E., Laing I., Longson D., and Davies D. Long-term treatment of Nelson's syndrome with sodium valproate. Clin. Endocrinol. (Oxf.) 28 (1988) 195-204
9. Mercado-Assis L.B., Yanowski J.A., Tracer H.L., Chick C.L., and Cutler G.B. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome. J. Clin. Endocrinol. Metab. 82 (1997) 514-517
10. Kasperlik-Zaluska A.A., Zgliczynski W., Jeske W., and Zdunowski P. ACTH response to somatostatin, valproic acid and dexamethasone in Nelson's syndrome. Neuroendocrinol. Lett. 26 (2005) 709-712
11. Petrini L., Gasperi M., Pilosu R., Marcello A., and Martino E. Long-term treatment of Nelson's syndrome by octreotide: a case report. J. Endocrinol. Invest. 17 (1994) 135-139
12. De Herder W.W., Van der Lely A.J., and Lamberts S.W. Somatostatin analogue treatment of neuroendocrine tumours. Postgrad. Med. J. 72 (1996) 403-408
13. Bruns C., Lewis I., Briner U., Meno-Tetang G., and Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146 (2002) 707-716
14. Hofland L.J., Van der Hoek J., Feelders R., Van Aken M.O., Van Koetsveld P.M., Waaijers M., et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptors type 5. Eur. J. Endocrinol. 152 (2005) 645-654
15. Batista D.L., Zhang X., Gejman R., Ansell P.J., Zhou Y., Johnson S.A., et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91 (2006) 4482-4488
16. Andreassen M., and Kristensen L.O. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur. J. Endocrinol. 153 (2005) 503-505
17. Mullan K.R., Leslie H., McCance D.R., Sheridan B., and Atkinson A.B. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin. Endoc. 64 (2006) 519-522
18. Pivonello R., Faggiano A., Di Salle F., Filipella M., Lombardi G., and Colao A. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J. Endocrinol. Invest. 22 (1999) 860-865
19. Casulari L.A., Naves L.A., Mello P.A., Pereira Neto A., and Papadia C. Nelson's syndrome: complete remission with cabergoline, but not with bromocriptine or cyproheptadine treatment. Horm. Res. 62 (2004) 300-305
20. Shraga-Slutzky I., Shimon I., and Weinshtein R. Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment. Pituitary 9 (2006) 151-154